Interstitial lung disease in an adult patient with dermatomyositis and anti-NXP2 autoantibody

European Respiratory Review

Volumn 24, Issue 136, 2015, Pages 370-372

  Gossez, Morgane ^a   Levesque, Marianne ^b   Khouatra, Chahéra ^c   Cottin, Vincent ^c   Garnier, Lorna ^a   Fabien, Nicole ^a  

^a CENTRE HOSPITALIER LYON SUD   (France)

^b HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CREATINE KINASE; FRUCTOSE BISPHOSPHATE ALDOLASE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLATE MOFETIL; NUCLEAR MATRIX PROTEIN 2 AUTOANTIBODY; PREDNISONE; UNCLASSIFIED DRUG; ADENOSINE TRIPHOSPHATASE; BIOLOGICAL MARKER; DNA BINDING PROTEIN; IMMUNOSUPPRESSIVE AGENT; MORC3 PROTEIN, HUMAN;

ADULT; CASE REPORT; CD4+ T LYMPHOCYTE; COUGHING; CREATINE KINASE BLOOD LEVEL; DELTOID MUSCLE; DERMATOMYOSITIS; DYSPNEA; ELECTROMYOGRAPHY; ERYTHEMA; FASCIITIS; FEMALE; FEVER; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN TISSUE; INTERSTITIAL LUNG DISEASE; LETTER; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MUSCLE BIOPSY; MUSCLE CONTRACTURE; MYALGIA; ORGANIZING PNEUMONIA; PLASMA CELL; TACHYPNEA; THERAPY RESISTANCE; TRAPEZIUS MUSCLE; AUTOIMMUNITY; BLOOD; COMPUTER ASSISTED TOMOGRAPHY; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; TREATMENT OUTCOME;

ADENOSINE TRIPHOSPHATASES; ADULT; AUTOANTIBODIES; AUTOIMMUNITY; BIOMARKERS; DERMATOMYOSITIS; DNA-BINDING PROTEINS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES, INTERSTITIAL; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84930433471     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00006714     Document Type: Letter

References (15)

1. Lazarou IN, Guerne PA. Classification, diagnosis, and management of idiopathic inflammatory myopathies. J Rheumatol 2013; 40: 550–564.
2. Lega JC, Fabien N, Reynaud Q, et al. The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 2014; 13: 883–891.
3. Rider LG, Katz JD, Jones OY. Developments in the classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 2013; 39: 877–904.
4. Mimura Y, Takahashi K, Kawata K, et al. Two-step colocalization of MORC3 with PML nuclear bodies. J Cell Sci 2010; 123: 2014–2024.
5. Betteridge Z, Gunawardena H, North J, et al. Identification of a novel autoantibody directed against small ubiquitin-like modifier activating enzyme in dermatomyositis. Arthritis Rheum 2007; 56: 3132–3137.
6. Salimbene I, Leli I, Valente S. Respiratory failure in a patient with dermatomyositis. Multidiscip Respir Med 2013; 8: 27.
7. Oddis CV, Fertig N, Goel A, et al. Clinical and serological characterisation of the anti-MJ antibody in childhood myositis. Arthritis Rheum 1997; 40: S139.
8. Gunawardena H, Wedderburn LR, Chinoy H, et al. Autoantibodies to a 140-kd protein in juvenile dermatomyositis are associated with calcinosis. Arthritis Rheum 2009; 60: 1807–1814.
9. Gunawardena H, Betteridge ZE, McHugh NJ. Myositis-specific autoantibodies: their clinical and pathogenic significance in disease expression. Rheumatology (Oxford) 2009; 48: 607–612.
10. Sugiura K, Muro Y, Akiyama M. Autoantibodies to nuclear matrix protein 2/MJ in adult-onset dermatomyositis with severe calcinosis. J Am Acad Dermatol 2012; 67: e167–e168.
11. Ichimura Y, Matsushita T, Hamaguchi Y, et al. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Ann Rheum Dis 2012; 71: 710–713.
12. Fiorentino DF, Chung LS, Christopher-Stine L, et al. Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ. Arthritis Rheum 2013; 65: 2954–2962.
13. Ceribelli A, Fredi M, Taraborelli M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther 2012; 14: R97.
14. Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013; 107: 745–752.
15. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J 2006; 28: 893–896.